Analyst Price Targets — GH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 11:40 am | — | Piper Sandler | $130.00 | $94.42 | TheFly | Guardant Health price target raised to $130 from $120 at Piper Sandler |
| February 23, 2026 2:41 pm | — | Raymond James | $129.00 | $97.49 | TheFly | Guardant Health price target raised to $129 from $115 at Raymond James |
| February 20, 2026 12:56 pm | — | Evercore ISI | $110.00 | $106.84 | TheFly | Guardant Health price target raised to $110 from $105 at Evercore ISI |
| February 20, 2026 12:11 pm | — | BTIG | $145.00 | $106.38 | TheFly | Guardant Health price target raised to $145 from $140 at BTIG |
| February 20, 2026 12:09 pm | — | Stifel Nicolaus | $130.00 | $106.38 | TheFly | Guardant Health price target raised to $130 from $120 at Stifel |
| February 20, 2026 11:47 am | — | Canaccord Genuity | $135.00 | $106.38 | TheFly | Guardant Health price target raised to $135 from $125 at Canaccord |
| February 20, 2026 10:04 am | — | Barclays | $130.00 | $106.38 | TheFly | Guardant Health price target raised to $130 from $120 at Barclays |
| February 17, 2026 10:08 am | Catherine Schulte | Robert W. Baird | $120.00 | $104.85 | TheFly | Guardant Health initiated with an Outperform at Baird |
| January 30, 2026 2:02 pm | — | UBS | $175.00 | $111.00 | TheFly | Guardant Health price target raised to $175 from $110 at UBS |
| January 26, 2026 2:35 pm | — | Guggenheim | $135.00 | $115.69 | TheFly | Guardant Health price target raised to $135 from $115 at Guggenheim |
Latest News for GH
Coherent is expected to continue to benefit from a transition to products that enable faster throughput speeds, while prior constraints on manufacturing capacity appear to be alleviating. BrightSpring Health Services reported another strong quarter with both revenues and EBITDA up significantly, far outpacing its historical growth rate prior to going public in 2024. Varonis Systems, which provides data protection…
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 41,852 shares of its common stock to 88 new non-executive employees and one non-qualified stock option award to purchase 4,965…
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetization. The Russell 1000 Value Index returned 3.81% during the quarter, outperforming the Russell 1000 Growth Index's return of 1.12% by nearly 270 basis points. Under its 'pivot to growth' strategy, Teva has expanded…
Granite Investment Partners LLC lessened its stake in Guardant Health, Inc. (NASDAQ: GH) by 52.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 185,301 shares of the company's stock after selling 201,565 shares during the period. Granite Investment Partners LLC owned
Assetmark Inc. increased its holdings in shares of Guardant Health, Inc. (NASDAQ: GH) by 18,838.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,257 shares of the company's stock after acquiring an additional 13,187 shares during the period. Assetmark Inc.'s holdings in
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.